Precision Sells Off Autoimmune Rights For Allogeneic CAR-T To TG Therapeutics

TG, which has seen growing sales for Briumvi in multiple sclerosis, is expanding into CAR-T for immunology as Precision pivots to in vivo gene therapies.

TG and Precision signed a deal for Precision's off-the-shelf CAR-T, both companies having recently made strategic pivots. • Source: Shutterstock

As sales of its CD20-directed monoclonal antibody for multiple sclerosis pick up speed, TG Therapeutics, Inc. is furthering its pivot from oncology into immunology through a deal with Precision BioSciences, Inc. to develop a CD19-directed allogeneic CAR-T cell therapy for autoimmune diseases. Precision itself had announced plans over the summer to exit development of the asset, azercabtagene zapreleucel (azer-cel), and make its own strategic pivot.

TG announced the global licensing deal for exclusive worldwide rights to develop and commercialize azer-cel in non-oncology indications on 9 January, and will pay Precision $17.5m consisting of a $7.5m upfront payment as well as near-term economics

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

16 May 2025

• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.